Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

CAFC: Judge Newman again questions the constitutionality of “do over” patent reexamination: In re Baxter International, Inc (Patents Post-Grant) (WHDA) (Inventive Step) (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Nobel Laureate, other experts hail WHO effort on medicines R&D framework (IP Watch)

Drug safety needs global cooperation of drug regulators, officials say (IP Watch)

WHO Director Chan opens annual assembly with optimism, despite economic woes (IP Watch)

WHO assembly highlights concern for healthcare IP (Patent Quality Matters)

Australia: New momentum to ban gene patents (IP Whiteboard)

India’s generics-big pharma battle drops drug prices, raises legal debate (IP Watch)

Kenyan resolution to the 65th World Health Assembly: WHO Convention on Research and Development Financing and Coordination (KEI)

South Africa hopes new Bill brings traditional knowledge protection (IP Watch)

US: BIO memo opposing transparency of drug development costs, sales, prices, and clinical trial outcomes (KEI)

US: FDA holds public hearing on biosimilar draft guidance (Patent Docs)

US: USPTO posts comments on genetic diagnostic testing (Patent Docs)

US: Survey finds that many U.S. consumers have favorable impression of plant and animal biotechnology (Patent Docs)

US: CAFC: Judge Newman again questions the constitutionality of “do over” patent reexamination: In re Baxter International, Inc (Patents Post-Grant) (WHDA) (Inventive Step) (Patent Docs)

US: U.S. courts look at method of use patents in generic drug/ANDA litigation: Caraco v Novo Nordisk (Prandin) and Bayer Schering v Lupin (Yasmin) (Kluwer Patent Blog)

US: Mayo v. Prometheus: Thought leaders express concern and evaluate the impact (BIOtechNOW)

US: Applying Prometheus to Myriad: possible outcomes (Intellectual Property Law Blog)

US: Abbott petitions FDA on biosimilars; argues Fifth Amendment takings clause (FDA Law Blog)

 

Products

Ablify (Aripiprazole) – US: Otsuka files patent infringement suit against Amneal Pharmaceuticals in response to Para IV challenge (Patent Docs)

Altace (Ramipril) – US: CAFC: In Re Montgomery: Inherently therapeutic (Pharma Patents)

Atelvia (Risedronate) – US: Warner Chilcott  files patent infringement suit against Ranbaxy in response to Para IV challenge (Patent Docs)

Azilect (Rasagilimine) – US: Teva Neuroscience files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs)

Coenzyme Q10 – US: ALJ Rogers sanctions Kaneka in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog)

Coversyl (Perindopril) – UK: Servier v Apotex: Illegality earns $17.5 million in damages (IP Osgoode)

Lexapro (Escitalopram) – Australia: Appeals Tribunal preserves confidentiality as Lexapro saga extends: Aspen and Commissioner of Patents (Patentology)

Losec (Omeprazole) – EU: CJEU: AstraZeneca appeal against competition law breach and level of fine imposed on it should be rejected, legal advisor says (Out-Law)

Ofirmev (Acetaminophen) – US: Exela files suit over USPTO’s refusal to vacate decision to revive application relating to licensee Cadence’s Ofirmev (Patent Docs)

Stalevo (Entacapone, Levodopa, and Carbidopa) – US: Orion files patent infringement suit against Mylan in response to Para IV challenge (Patent Docs)